Uncategorized
Nicox transfers international commercial operations to GHO Capital
Nicox has entered into an agreement with GHO Capital to transfer its European and international commercial operations, valued at up to €26 million, to a newly founded private company focused on the commercialization of a portfolio of ophthalmic products in Europe, according to a press release from Nicox. Rights to Nicox’s unencumbered research and development pipeline programs, which includes AC-170 for allergic conjunctivitis, among others, will remain with Nicox. Furthermore, “rights under the latanoprostene bunod agreement with Bausch + Lomb remain entirely with Nicox,” the release said. Both programs have (Read more...)